Breyanzi (lisocabtagene maraleucel) is now approved for adults with relapsed or refractory follicular lymphoma who have received at least two other systemic therapies, according to a May 15 news release from BMS.
In a clinical trial of 101 patients, 94% of study participants achieved a complete response and 97% showed an overall response rate.
The one-time infusion therapy is also approved for relapsed or refractory large B-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia, and small lymphocytic lymphoma.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
